CS
IMCR icon

Candriam SCA’s Immunocore IMCR Stock Holding History

Candriam SCA’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
373,046
+103,317
+38% +$3.06M 0.05% 266
2026
Q1 		$8.13M Hold
269,729
– – 0.04% 312
2025
Q4 		$9.36M Hold
269,729
– – 0.05% 279
2025
Q3 		$9.8M Buy
269,729
+134,950
+100% +$4.58M 0.05% 279
2025
Q2 		$4.23M Sell
134,779
-6
-0% -$186 0.02% 380
2025
Q1 		$4M Hold
134,785
– – 0.03% 375
2024
Q4 		$3.98M Sell
134,785
-5,221
-4% -$165K 0.02% 389
2024
Q3 		$4.36M Sell
140,006
-173,417
-55% -$6.31M 0.03% 387
2024
Q2 		$10.6M Buy
313,423
+124,417
+66% +$6.35M 0.06% 247
2024
Q1 		$12.3M Buy
189,006
+45,000
+31% +$3.09M 0.08% 233
2023
Q4 		$9.84M Sell
144,006
-149,005
-51% -$7.74M 0.07% 253
2023
Q3 		$15.2M Sell
293,011
-57,003
-16% -$3.37M 0.11% 180
2023
Q2 		$21M Buy
350,014
+32,254
+10% +$1.84M 0.15% 154
2023
Q1 		$14.5M Buy
317,760
+198,685
+167% +$11.2M 0.1% 209
2022
Q4 		$6.8M Sell
119,075
-247
-0.2% -$13.9K 0.05% 333
2022
Q3 		$5.6M Buy
+119,322
New +$5.69M 0.04% 358

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Candriam SCA's IMCR Position: Q2 2026 in Review

Candriam SCA increased its Immunocore (IMCR) stake by 38% in Q2 2026, buying an estimated $3.06M and bringing the position to 373,046 shares worth $11.8M. The position accounts for 0.05% of the portfolio, ranked #266.

Candriam SCA first reported a position in IMCR in Q3 2022 and has held it in 16 quarters since. The position peaked at $21M in Q2 2023. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Candriam SCA held 373,046 shares of Immunocore worth $11.8M as of Q2 2026.
  • Candriam SCA bought 103,317 Immunocore shares in Q2 2026, an estimated $3.06M.
  • Immunocore made up 0.05% of Candriam SCA's portfolio in Q2 2026, its #266 holding.
  • Candriam SCA first reported a position in Immunocore in Q3 2022 and has held it in 16 quarters since.
  • Candriam SCA's Immunocore position peaked at $21M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.